Biocon's New Leadership Charts Course as Global Pharmaceutical Player

Biocon Ltd. Enters New Chapter Under Shreehas Tambe

April 1, 2024 marks a significant milestone for Biocon Ltd., India's largest biopharmaceutical company by revenue, as Shreehas Tambe assumes the role of Chief Executive Officer and Managing Director. This transition comes at a critical juncture as the company seeks to deepen its participation in the global value chain in biosimilars, complex generics, and peptides.

Integration Complete

Following the full integration of Biocon Biologics into Biocon Ltd., the leadership transition is poised to drive a shift from a cost leadership model to capability leadership. Over the past two years, Biocon has absorbed Viatris' biosimilars business, rationalized overlapping structures, and expanded its commercial footprint across the US, Europe, and emerging markets.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

From Volume to Value

Historically, Biocon operated two distinct engines: a biosimilars business organized around therapy areas, and a generics business driven by filings, exclusivities, and cost arbitrage. Tambe has stated that this model has reached its limits, and the company plans to align both biosimilars and small molecules around therapy areas such as diabetes, oncology, and immunology. This approach is expected to deliver higher margins and more durable growth.

GLP-1s: Selective Approach

Biocon will adopt a selective approach to GLP-1 therapies, where patent expiries have triggered a rush of launches in India. While the company has already built and commercialized a peptide portfolio anchored by liraglutide, it will wait for the dust to settle before deciding on entry into the Indian market.

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year

Geopolitics and Supply Chain

The conflict in West Asia has pushed up freight and logistics costs, adding volatility to supply chains. Tambe expects the impact to be transient, and the company will assess pass-through options once the quarter closes.

Leadership Succession

Tambe's appointment formalizes a leadership succession that has been in the making since Biocon Biologics emerged as one of the world's top five biosimilar companies by revenue. Executive Chairperson Kiran Mazumdar-Shaw has credited him with driving several of the company's most consequential strategic moves, including the Viatris acquisition.